A targetable cue in T-cell malignancy

Abstract

In this issue of Blood, De Smedt et al demonstrate that glucocorticoid treatment of a subset of T-cell acute lymphoblastic leukemia/T-cell acute lymphoblastic lymphoma (T-ALL/T-LBL) cells upregulates PIM1 expression, creating a synergistic vulnerability and potent antileukemic effect with PIM1 inhibitors in a preclinical model.(1)